Healthcare
Adaptimmune Therapeutics PLC (ADAPY)
As-reported financials and recent SEC filings for Adaptimmune Therapeutics PLC, latest fiscal period FY2024. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$178.0M
Net income
$-70.8M
Net margin
-39.8%
Diluted EPS
$-0.05
ROE
-597.6%
P/E (TTM)
—
Market cap
—
Debt / equity
4.2×
Income statement (as reported)
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $178.0M | $60.3M | $27.1M | $6.1M | $4.0M |
| Gross profit | — | — | — | — | — |
| Operating income | $-68.8M | $-139.7M | $-164.0M | $-162.2M | $-133.4M |
| Net income | $-70.8M | $-113.9M | $-165.5M | $-158.1M | $-130.1M |
| Diluted EPS | $-0.05 | $-0.09 | $-0.17 | $-0.17 | $-0.15 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
RW2026-04-22
View on EDGAR →SCHEDULE 13G2026-02-17
View on EDGAR →EFFECT2025-11-14
View on EDGAR →SCHEDULE 13G/A2025-11-14
View on EDGAR →424B32025-11-13
View on EDGAR →15-12G2025-11-13
View on EDGAR →S-8 POS2025-10-28
View on EDGAR →S-8 POS2025-10-28
View on EDGAR →Largest Healthcare peers
Go deeper on ADAPY
Search Adaptimmune Therapeutics PLC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.